Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
$9.68
$0.61
$24.20
$820K1.4119,299 shs416,900 shs
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
$1.11
-0.9%
$1.16
$0.72
$6.45
$11.02M0.22386,977 shs212,683 shs
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
$7.30
-24.5%
$10.15
$3.60
$11.99
$101.90M0.4342,743 shs32,633 shs
PolarityTE, Inc. stock logo
PTE
PolarityTE
$0.37
$0.20
$1.90
$1.78M1.15249,591 shs8.50 million shs
Surface Oncology, Inc. stock logo
SURF
Surface Oncology
$1.07
$1.01
$0.56
$1.43
$65.08M1.75430,375 shsN/A
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
0.00%0.00%0.00%0.00%0.00%
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
+5.66%-5.88%-2.59%-5.88%-77.94%
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
-3.54%-7.07%+25.28%-14.02%+42.36%
PolarityTE, Inc. stock logo
PTE
PolarityTE
0.00%0.00%0.00%0.00%0.00%
Surface Oncology, Inc. stock logo
SURF
Surface Oncology
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
4.4285 of 5 stars
3.54.00.04.72.70.80.6
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
4.3203 of 5 stars
3.53.00.04.40.62.51.3
PolarityTE, Inc. stock logo
PTE
PolarityTE
N/AN/AN/AN/AN/AN/AN/AN/A
Surface Oncology, Inc. stock logo
SURF
Surface Oncology
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
0.00
N/AN/AN/A
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
3.00
Buy$30.002,602.70% Upside
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
3.00
Buy$12.0064.41% Upside
PolarityTE, Inc. stock logo
PTE
PolarityTE
0.00
N/AN/AN/A
Surface Oncology, Inc. stock logo
SURF
Surface Oncology
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
$117.63M0.00N/A0.02($127.17) per share0.00
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
N/AN/AN/AN/A($1.36) per shareN/A
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
$50.15M2.01N/AN/A($0.14) per share-52.14
PolarityTE, Inc. stock logo
PTE
PolarityTE
$810K0.00N/AN/A$2.30 per share0.00
Surface Oncology, Inc. stock logo
SURF
Surface Oncology
$30M2.17N/AN/A$0.81 per share1.32
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
-$252.85M-$203.83N/AN/AN/A-214.95%-2,206.93%-83.28%N/A
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
-$11.62M-$3.36N/AN/AN/AN/AN/A-519.50%8/13/2025 (Estimated)
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
-$7.28M-$0.0616.75N/A10.97%656.65%24.04%N/A
PolarityTE, Inc. stock logo
PTE
PolarityTE
-$7.83M-$3.28N/AN/AN/AN/A-106.08%-76.91%N/A
Surface Oncology, Inc. stock logo
SURF
Surface Oncology
-$63.59M-$1.53N/AN/AN/AN/A-107.81%-65.57%N/A

Latest ACOR, PTE, BCLI, CSBR, and SURF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
-$0.38-$0.45-$0.07-$0.45N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
N/AN/AN/AN/AN/A
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
N/AN/AN/AN/AN/A
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
N/AN/AN/AN/AN/A
PolarityTE, Inc. stock logo
PTE
PolarityTE
N/AN/AN/AN/AN/A
Surface Oncology, Inc. stock logo
SURF
Surface Oncology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
3.07
0.33
0.26
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
N/A
0.21
0.21
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
N/A
0.99
0.99
PolarityTE, Inc. stock logo
PTE
PolarityTE
N/A
4.11
4.11
Surface Oncology, Inc. stock logo
SURF
Surface Oncology
N/A
3.60
3.60

Institutional Ownership

CompanyInstitutional Ownership
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
12.71%
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
14.33%
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
41.30%
PolarityTE, Inc. stock logo
PTE
PolarityTE
11.75%
Surface Oncology, Inc. stock logo
SURF
Surface Oncology
37.21%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
1111.24 million1.21 millionNo Data
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
409.84 million8.74 millionOptionable
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
14313.83 million7.33 millionOptionable
PolarityTE, Inc. stock logo
PTE
PolarityTE
427.38 million6.98 millionOptionable
Surface Oncology, Inc. stock logo
SURF
Surface Oncology
3560.82 million53.53 millionNot Optionable

Recent News About These Companies

Q3 2024 Heron Therapeutics Inc Earnings Call
How wearable tech can help women fight breast cancer

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Acorda Therapeutics stock logo

Acorda Therapeutics NASDAQ:ACOR

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.

Brainstorm Cell Therapeutics stock logo

Brainstorm Cell Therapeutics NASDAQ:BCLI

$1.11 -0.01 (-0.89%)
Closing price 04:00 PM Eastern
Extended Trading
$1.06 -0.05 (-4.05%)
As of 07:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Champions Oncology stock logo

Champions Oncology NASDAQ:CSBR

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

PolarityTE stock logo

PolarityTE NASDAQ:PTE

PolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.

Surface Oncology stock logo

Surface Oncology NASDAQ:SURF

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited and Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. As of September 8, 2023, Surface Oncology, Inc. operates as a subsidiary of Coherus BioSciences, Inc.